UNASSIGNED: Based on the TCGA database and cohort of HCC patients, we investigated the expression patterns and prognostic value of SNRNP70 in HCC. Then, the combination of SNRNP70 and alpha-fetoprotein (AFP) in 278 HCC cases was analyzed. Next, western blotting and immunohistochemistry were used to detect the expression of SNRNP70 in nucleus and cytoplasm. Finally, Cell Counting Kit-8 (CCK-8) and scratch wound healing assays were used to detect the effect of SNRNP70 on the proliferation and migration of HCC cells.
UNASSIGNED: SNRNP70 was highly expressed in HCC. Its expression was increasingly high during the progression of HCC and was positively related to immune infiltration cells. Higher SNRNP70 expression indicated a poor outcome of HCC patients. In addition, nuclear SNRNP70/AFP combination could be a prognostic biomarker for overall survival and recurrence. Cell experiments confirmed that knockdown of SNRNP70 inhibited the proliferation and migration of HCC cells.
UNASSIGNED: SNRNP70 may be a new biomarker for HCC progression and HCC diagnosis as well as prognosis. SNRNP70 combined with serum AFP may indicate the prognosis and recurrence status of HCC patients after operation.
■基于TCGA数据库和HCC患者队列,我们研究了SNRNP70在HCC中的表达模式和预后价值。然后,分析了278例HCC病例中SNRNP70和甲胎蛋白(AFP)的组合。接下来,免疫印迹法和免疫组化法检测SNRNP70在细胞核和细胞质中的表达。最后,细胞计数试剂盒-8(CCK-8)和划痕伤口愈合试验用于检测SNRNP70对HCC细胞增殖和迁移的影响。
■SNRNP70在HCC中高表达。其表达在肝癌进展过程中日益增高,并与免疫浸润细胞呈正相关。较高的SNRNP70表达表明HCC患者的预后较差。此外,核SNRNP70/AFP组合可能是总体生存和复发的预后生物标志物。细胞实验证实,敲低SNRNP70抑制HCC细胞的增殖和迁移。
■SNRNP70可能是HCC进展和HCC诊断以及预后的新生物标志物。SNRNP70联合血清AFP可提示HCC患者的预后及术后复发情况。